Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07383506 · ClinicalTrials.gov registry record · Phase 1
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Cogent Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07383506 is a Phase 1 study that is actively recruiting participants, run by Cogent Biosciences. The registered enrollment target is 90 participants.
The verdict
NCT07383506, a Phase 1 study, is actively recruiting participants, sponsored by Cogent Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations
Interventions
- DRUG CGT6297
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07383506
The ClinicalTrials.gov registry entry for NCT07383506 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CGT6297 is the first listed.
NCT07383506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07383506 about?
NCT07383506 is a clinical study titled "A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors". This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA ...
What is the current status of trial NCT07383506?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2029-08.
What interventions are being tested in trial NCT07383506?
The interventions under investigation include: CGT6297 (DRUG).
Who is sponsoring clinical trial NCT07383506?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.